Fresenius reports 6.8% stake in Humacyte

Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares.

Rhea-AI Filing Summary

Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte common stock, equal to 6.8% of the outstanding voting shares. All 18,312,735 shares are issued, outstanding, and directly owned by Fresenius Medical Care Holdings, Inc., with Fresenius Medical Care AG as indirect sole shareholder and deemed beneficial owner.

The stake percentage decreased from 8.4% to 6.8% solely because Humacyte’s total outstanding common shares increased to 269,638,156 as of June 12, 2026; Fresenius has neither acquired nor disposed of Humacyte shares since its initial 2021 filing. The amendment also notes that Mollie Miller became a Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. effective May 1, 2026.

Key Figures

Beneficial ownership: 18,312,735 shares Percent of class: 6.8% Total shares outstanding: 269,638,156 shares +3 more

6 metrics

Beneficial ownership 18,312,735 shares Humacyte common stock reported by Fresenius Medical Care Holdings, Inc.

Percent of class 6.8% Portion of Humacyte outstanding voting shares held by Fresenius entities

Total shares outstanding 269,638,156 shares Humacyte common shares outstanding as of June 12, 2026

Shares outstanding baseline 222,019,108 shares Humacyte shares outstanding on May 11, 2026 from Form 10-Q cover page

Additional shares issued 47,619,048 shares Humacyte shares issued on June 12, 2025 per Prospectus Supplement

Prior reported ownership 8.4% Fresenius percentage of Humacyte reported in Amendments Nos. 7 and 8

Key Terms

beneficial owner, shared voting power, shared dispositive power, percent of class, +2 more

6 terms

beneficial owner financial

"FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power financial

"Shared Voting Power 18,312,735.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 18,312,735.00"

percent of class financial

"Percent of class represented by amount in Row (11) 6.8 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Business Combination Agreement financial

"exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement"

A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.

Schedule 13D regulatory

"previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Humacyte (HUMA) shares does Fresenius beneficially own?

Fresenius Medical Care Holdings, Inc. beneficially owns 18,312,735 Humacyte common shares. These shares are issued, outstanding, and directly held by Fresenius Medical Care Holdings, with Fresenius Medical Care AG treated as an indirect beneficial owner through its sole ownership of the subsidiary.

What percentage of Humacyte (HUMA) does Fresenius currently hold?

Fresenius reports beneficial ownership of approximately 6.8% of Humacyte’s outstanding voting common shares. This percentage is based on 269,638,156 Humacyte shares outstanding as of June 12, 2026, combining previously outstanding shares and additional shares issued by Humacyte.

Why did Fresenius’s ownership percentage in Humacyte (HUMA) fall from 8.4% to 6.8%?

The reported ownership percentage fell from 8.4% to 6.8% because Humacyte’s total outstanding common shares increased. Fresenius states it has not bought or sold Humacyte shares since its initial Schedule 13D, so the change reflects dilution from new shares issued by Humacyte.

How did Humacyte’s total outstanding shares reach 269,638,156?

Humacyte’s 269,638,156 outstanding shares reflect 222,019,108 shares outstanding on May 11, 2026, plus 47,619,048 shares issued on June 12, 2025. These figures come from Humacyte’s Form 10-Q cover page and a Prospectus Supplement referenced in the ownership calculation.

Who directly owns the Humacyte (HUMA) shares reported by Fresenius?

All 18,312,735 Humacyte shares are directly owned by Fresenius Medical Care Holdings, Inc. Fresenius Medical Care AG is the indirect sole shareholder of this entity and may be deemed a beneficial owner of the same shares through its ownership structure, as described in the amendment.

What management change at Fresenius is mentioned in this Humacyte (HUMA) filing?

Effective May 1, 2026, Mollie Miller was appointed Vice President and Assistant Treasurer of Fresenius Medical Care Holdings, Inc. She serves as Director of Taxes at the company and is a U.S. citizen, with her business address listed at the firm’s New York location.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 09:53 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 009)

HUMACYTE, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

020751103

(CUSIP Number)

Robert A. Grauman
145 West 86 Street,
New York, NY, 10024
646 202-2932

Thomas D. Brouillard
Fresenius Medical Care Holdings, Inc., 920 Winter Street
Waltham, MA, 02451-1547
781 699 9000

Christof Koester
Fresenius Medical Care AG, Else-Kroener Strasse 1
Bad Homburg, 2M, 61352
011 49 6172 609 0

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 020751103

1

Name of reporting person

Fresenius Medical Care Holdings, Inc.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,312,735.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,312,735.00

11

Aggregate amount beneficially owned by each reporting person

18,312,735.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP Number(s): 020751103

1

Name of reporting person

Fresenius Medical Care AG

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,312,735.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,312,735.00

11

Aggregate amount beneficially owned by each reporting person

18,312,735.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.8 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: HUMACYTE, INC.
(c)	Address of Issuer's Principal Executive Offices: 2525 East North Carolina Highway 54, Durham, NORTH CAROLINA , 27713.
Item 1 Comment: This Amendment No. 9 amends certain information contained in the Schedule 13D originally filed by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") on September 2, 2021, as previously amended by Amendment No. 1 filed December 1, 2023, Amendment No. 2 filed March 7, 2024, Amendment No 3 filed November 18, 2024, Amendment No 4 filed May 22, 2025, Amendment No 5 filed solely by FME AG on October 16 2025, Amendment No. 6 filed by FME AG and FMCH on January 9, 2026, Amendment No. 7 filed March 24, 2026, and Amendment No 8 filed Apil 27, 2026 (as so amended, the "Schedule 13D"), with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 9 does not modify any of the information previously reported on the Schedule 13D.
Item 2.	Identity and Background
(a)	Effective May 1, 2026 Ms. Mollie Miller was appointed a Vice President and Assistant Treasurer of FMCH.
(b)	Ms. Miller's business address is c/o FMCH, at the address of FMCH set forth in the Schedule 13D.
(c)	Ms. Miller's principal occupation or employment is as Director of Taxes at FMCH.
(d)	During the last five years, Ms. Miller has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or been a party to a civil proceeding of a United States judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(e)	See (d) above.
(f)	Ms. Miller is a U.S. citizen.
Item 5.	Interest in Securities of the Issuer
(a)	On the date of this Schedule 13D (Amendment No. 9), FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock, constituting approximately 6.8% of the Issuer's outstanding voting shares. Such percentage ownership is calculated by reference to a total of 269,638,156 shares outstanding as of June 12, 2026, comprising (i) 222,019,108 shares outstanding on May 11, 2026, as shown on the cover page of the Issuer's Form 10-Q filed May 13, 2026, plus (ii) 47,619,048 shares issued on June 12, 2025, as reported in the Issuer's Prospectus Supplement dated June 10, 2026. All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH. Such 18,312,735 shares of Common Stock exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement described in the initial Schedule 13D, and FME AG and FMCH disclaim any present beneficial ownership of any such additional shares.
(b)	As the record owner of the 18,312,735 shares of Common Stock reported in this Schedule 13D (Amendment No 9), FMCH possesses voting and dispositive power over such shares. FME AG is the indirect sole shareholder of FMCH and may be deemed to be a beneficial owner of such shares.
(c)	The decrease in the percentage beneficial ownership reported herein from 8.4% as reported in Schedule 13D (Amendments Nos. 7 and 8) to 6.8%, as reported herein, results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 8 to this Schedule 13D, as describe in Item 5(a). Neither FME AG nor FMCH has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of their initial Schedule 13D in September 2021.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Fresenius Medical Care Holdings, Inc.

Signature:	/s/ Mollie Miller
Name/Title:	Mollie Miller, VP and Asst. Treasurer
Date:	06/15/2026

Fresenius Medical Care AG

Signature:	/s/ ppa Angela Koelbl
Name/Title:	Dr. Angela Koelbl, Registered Manager (Prokurist)
Date:	06/15/2026

Signature:	/s/ ppa Christof Koester
Name/Title:	Christof Koester (Registered Manager (Prokurist)
Date:	06/15/2026